search
Back to results

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

Primary Purpose

Urinary Calculi, Urinary Stones, Urinary Tract Stones

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
OMS201
Vehicle
Sponsored by
Omeros Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Calculi focused on measuring Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi, Kidney Stones, Calculi, Urolithotomy, Ureteroscopy

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 - 65 years of age.
  • Subject is undergoing retrograde ureteroscopic removal of renal-collecting system or ureteral stones for which general anesthesia will be used.

Exclusion Criteria:

  • No allergies to any of the individual ingredients in OMS201.
  • Subject taking a prohibited medication.
  • Pregnant woman, nursing mother, or woman of child-bearing age unwilling to take contraception for the duration of the study.
  • Subject who has had a renal transplant, has a single kidney, has compromised renal function, or has evidence of papillary necrosis.
  • Subject who has evidence of a clinically significant urinary tract infection.
  • Subject who has a prior history of open or laparoscopic urinary tract surgery, or a history of a ureteral stricture.
  • Subject who has congenital anomalies that would engender an increased procedural safety risk.
  • Subject with a history of clinically significant chronic or episodic hypotension.
  • Subject's physical examination is significantly abnormal for purposes of the study as determined by the Investigator.
  • Subject's screening laboratory evaluations are not within normal limits AND abnormal results are determined by the Investigator to be clinically significant.
  • Subject is at risk from anesthesia.
  • Subject is on chronic diuretic use.
  • Subject has a present condition or history of any clinically significant medical disorder and is determined by the Investigator to be an unsuitable candidate for receipt of an investigational drug.

Sites / Locations

  • University of California Irvine Medical Center
  • Urology Center of Colorado
  • Urology Associates
  • Urology San Antonio Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

Drug

Vehicle

Outcomes

Primary Outcome Measures

Peak systemic exposure.

Secondary Outcome Measures

Safety
Degree of pain
Duration of the operation
Ease of placement of the ureteral access sheath

Full Information

First Posted
March 4, 2009
Last Updated
October 10, 2012
Sponsor
Omeros Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00857090
Brief Title
Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones
Official Title
Double-Blind, Placebo-Controlled, Concentration-Escalating, Pharmacokinetic Study Evaluating the Systemic Absorption, Safety, and Efficacy of OMS201 in Subjects Undergoing Ureteroscopic Treatment of Ureteral- or Renal Collecting System-Located Stones
Study Type
Interventional

2. Study Status

Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Omeros Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objectives of the study are to assess the systemic exposure, safety and efficacy of three concentrations of OMS201 in subjects undergoing retrograde ureteroscopic removal of upper urinary tract stones.
Detailed Description
The main objective is to estimate the systemic exposure of OMS201 in retrograde ureteroscopic treatment of upper urinary tract stones. Safety will be assessed by vital signs, laboratory values and adverse events. Exploratory efficacy measures will assess the effect of OMS201 on postoperative pain, duration of surgery and ease of placement of a ureteral access sheath.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi, Kidney Stones
Keywords
Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi, Kidney Stones, Calculi, Urolithotomy, Ureteroscopy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Drug
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Vehicle
Intervention Type
Drug
Intervention Name(s)
OMS201
Intervention Description
Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery
Intervention Type
Drug
Intervention Name(s)
Vehicle
Intervention Description
Stages 1-2: Vehicle irrigation solution during surgery
Primary Outcome Measure Information:
Title
Peak systemic exposure.
Time Frame
Day of surgery
Secondary Outcome Measure Information:
Title
Safety
Time Frame
Day 7
Title
Degree of pain
Time Frame
7 days
Title
Duration of the operation
Time Frame
Day of surgery
Title
Ease of placement of the ureteral access sheath
Time Frame
Day of surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 - 65 years of age. Subject is undergoing retrograde ureteroscopic removal of renal-collecting system or ureteral stones for which general anesthesia will be used. Exclusion Criteria: No allergies to any of the individual ingredients in OMS201. Subject taking a prohibited medication. Pregnant woman, nursing mother, or woman of child-bearing age unwilling to take contraception for the duration of the study. Subject who has had a renal transplant, has a single kidney, has compromised renal function, or has evidence of papillary necrosis. Subject who has evidence of a clinically significant urinary tract infection. Subject who has a prior history of open or laparoscopic urinary tract surgery, or a history of a ureteral stricture. Subject who has congenital anomalies that would engender an increased procedural safety risk. Subject with a history of clinically significant chronic or episodic hypotension. Subject's physical examination is significantly abnormal for purposes of the study as determined by the Investigator. Subject's screening laboratory evaluations are not within normal limits AND abnormal results are determined by the Investigator to be clinically significant. Subject is at risk from anesthesia. Subject is on chronic diuretic use. Subject has a present condition or history of any clinically significant medical disorder and is determined by the Investigator to be an unsuitable candidate for receipt of an investigational drug.
Facility Information:
Facility Name
University of California Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Urology Center of Colorado
City
Denver
State/Province
Colorado
ZIP/Postal Code
80211
Country
United States
Facility Name
Urology Associates
City
Nasville
State/Province
Tennessee
ZIP/Postal Code
37209
Country
United States
Facility Name
Urology San Antonio Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

We'll reach out to this number within 24 hrs